Mogamulizumab
- CAS No.
- 1159266-37-1
- Chemical Name:
- Mogamulizumab
- Synonyms
- KW-0761;Mogamulizumab;Mogamulizumab (anti-CCR4);Research Grade Mogamulizumab;Research Grade Mogamulizumab (DHE85301)
- CBNumber:
- CB54845963
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | YI437801BE |
| NCI Dictionary of Cancer Terms | mogamulizumab |
| ATC code | L01XC25 |
Mogamulizumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0617496 | Mogamulizumab 96.9% | 1159266-37-1 | 1mg | $320 | 2026-06-04 | Buy |
| ChemScene | CS-0617496 | Mogamulizumab 96.9% | 1159266-37-1 | 5mg | $1029 | 2026-06-04 | Buy |
| ChemScene | CS-0617496 | Mogamulizumab 96.9% | 1159266-37-1 | 10mg | $1842 | 2026-06-04 | Buy |
| aablocks | AA0294T2 | Mogamulizumab | 1159266-37-1 | 1mg | $215 | 2026-06-02 | Buy |
| Arctom | SLK-A2568 | Mogamulizumab (Anti-CCR4 / CD194) 99% | 1159266-37-1 | 1mg | $283 | 2026-05-26 | Buy |
Mogamulizumab Chemical Properties, Uses, Production
Uses
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)[1][2][3].
in vivo
Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4+CCR4+ T cells, with no adverse effect in dogs[4].
| Animal Model: | Murine xenograft model, constructed by using the immunodeficient NOG mouse and the EBV-positive NK-cell lymphoma cell line (SNK6)[2] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), together with PBMC transplantation; twice per week for 4 weeks. |
| Result: | Suppressed Tumor growth with vacuolar degeneration. |
IC 50
CCR4
References
[1] Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7(3):171-4. DOI:10.1177/2040620716636541
[2] Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20(19):5075-84. DOI:10.1158/1078-0432.CCR-14-0580
[3] Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211(2):238-48. DOI:10.1093/infdis/jiu438
[4] Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7(7):1175-1187. DOI:10.1158/2326-6066.CIR-18-0751
Mogamulizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Mogamulizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59929 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
View Latest Price from Mogamulizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Mogamulizumab
1159266-37-1
|
$243.00-1380.00 | 99.4% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Mogamulizumab
1159266-37-1
- $243.00-1380.00
- 99.4% (SEC-HPLC)
- TargetMol Chemicals Inc.
